Novavax originally showed its vaccine was safe and effective in a 30,000-person clinical trial. The FDA had been on track to ...

The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions.

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter ...

The U.S. Food and Drug Administration on Friday approved Novavax's COVID-19 vaccine, but placed additional conditions on ...

Covid shots are facing greater scrutiny from top federal health officials like RFK Jr. and the FDA's Marty Makary.

T he FDA issued an approval of Novavax’s COVID-19 vaccine, but with unusual restrictions, Lauran Neegaard of AP News reports. The FDA recently granted the company full approval ...

US regulators grant full approval to Novavax shot but sharply limit eligibility. New studies on heart risks required, raising ...

My name is Alec Stranahan, Senior Biotech Analyst covering Novavax at Bank of America. And I'm very pleased to be joined by many members of the senior leadership team at Novavax, including John ...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Novavax sees pathway to FDA approval after post-marketing commitments Swings to profit in Q1 Shares rise nearly 19% May 8 (Reuters) - Novavax (NVAX.O), opens new tab on Thursday tried to calm ...

Novavax (NASDAQ:NVAX) shares climbed ~35% in the premarket on Thursday after the COVID-19 vaccine maker lifted its full-year revenue outlook and reported Q1 2025 results significantly exceeding ...